Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis

Cancer Biology and Therapy

Volumn 14, Issue 2, 2013, Pages 146-154

  Slipicevic, Ana ^a   Oy, Geir Frode ^b   Rosnes, Anne Katrine Ree ^a   Stakkestad, Oystein ^a   Emilsen, Elisabeth ^a   Engesater, Birgit ^b   Malandsmo, Gunhild M ^b   Florenes, Vivi Ann ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Anisomycin; Caspases; Lexatumumab; Livin; Melanoma; Therapy; TRAIL

Indexed keywords

ANISOMYCIN; CASPASE 3; CASPASE 8; CASPASE 9; DEATH RECEPTOR 5; LEXATUMUMAB; LIVIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; PROTEIN P28; PROTEIN P30; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; X LINKED INHIBITOR OF APOPTOSIS;

ANTIGEN BINDING; APOPTOSIS; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIZATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MELANOMA CELL; METASTATIC MELANOMA; PROTEIN CLEAVAGE; PROTEIN SYNTHESIS INHIBITION;

ANISOMYCIN; CASPASES; LEXATUMUMAB; LIVIN; MELANOMA; THERAPY; TRAIL;

ANISOMYCIN; ANTIBODIES, MONOCLONAL; APOPTOSIS; CELL LINE, TUMOR; DRUG SYNERGISM; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84873475707     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.22953     Document Type: Article

References (41)

1. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004; 351:998-1012; PMID:15342808; http://dx.doi.org/10.1056/NEJMra041245.
2. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-16; PMID:21639808; http://dx.doi.org/10.1056/NEJMoa1103782.
3. Bouralexis S, Findlay DM, Evdokiou A. Death to the bad guys: targeting cancer via Apo2L/TRAIL. Apoptosis 2005; 10:35-51; PMID:15711921; http://dx.doi.org/10.1007/s10495-005-6060-0.
4. Lillehammer T, Engesaeter BO, Prasmickaite L, Maelandsmo GM, Fodstad O, Engebraaten O. Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrialmediated apoptosis in human melanoma cell lines. J Gene Med 2007; 9:440-51; PMID:17410615; http://dx.doi.org/10.1002/jgm.1036.
5. Yang A, Wilson NS, Ashkenazi A. Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation. Curr Opin Cell Biol 2010; 22:837-44; PMID:20813513; http://dx.doi.org/10.1016/j.ceb.2010.08.001.
6. Falschlehner C, Ganten TM, Koschny R, Schaefer U, Walczak H. TRAIL and other TRAIL receptor agonists as novel cancer therapeutics. Adv Exp Med Biol 2009; 647:195-206; PMID:19760076; http://dx.doi.org/10.1007/978-0-387-89520-8- 14.
7. Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 2010; 29:4752-65; PMID:20531300; http://dx.doi.org/10. 1038/onc.2010.221.
8. Koschny R, Walczak H, Ganten TM. The promise of TRAILpotential and risks of a novel anticancer therapy. J Mol Med (Berl) 2007; 85:923-35; PMID:17437073; http://dx.doi.org/10.1007/s00109-007-0194-1.
9. Ashley DM, Riffkin CD, Lovric MM, Mikeska T, Dobrovic A, Maxwell JA, et al. In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs. Br J Cancer 2008; 99:294-304; PMID:18594532; http://dx.doi.org/10.1038/sj.bjc.6604459.
10. Sun SY, Yue P, Hong WK, Lotan R. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells. Cancer Res 2000; 60:7149-55; PMID:11156424.
11. Amm HM, Oliver PG, Lee CH, Li Y, Buchsbaum DJ. Combined modality therapy with TRAIL or agonistic death receptor antibodies. Cancer Biol Ther 2011; 11:431-49; PMID:21263219; http://dx.doi.org/10.4161/cbt.11.5.14671.
12. Abayasiriwardana KS, Barbone D, Kim KU, Vivo C, Lee KK, Dansen TB, et al. Malignant mesothelioma cells are rapidly sensitized to TRAIL-induced apoptosis by low-dose anisomycin via Bim. Mol Cancer Ther 2007; 6:2766-76; PMID:17938269; http://dx.doi.org/10.1158/1535-7163.MCT-07-0278.
13. Sah NK, Munshi A, Kurland JF, McDonnell TJ, Su B, Meyn RE. Translation inhibitors sensitize prostate cancer cells to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by activating c-Jun N-terminal kinase. J Biol Chem 2003; 278:20593-602; PMID:12663665; http://dx.doi.org/10.1074/jbc.M211010200.
14. Xia S, Li Y, Rosen EM, Laterra J. Ribotoxic stress sensitizes glioblastoma cells to death receptor induced apoptosis: requirements for c-Jun NH2-terminal kinase and Bim. Mol Cancer Res 2007; 5:783-92; PMID:17699104; http://dx.doi.org/10.1158/1541-7786.MCR-06-0433.
15. Grollman AP. Inhibitors of protein biosynthesis. II. Mode of action of anisomycin. J Biol Chem 1967; 242:3226-33; PMID:6027796.
16. Hori T, Kondo T, Tabuchi Y, Takasaki I, Zhao QL, Kanamori M, et al. Molecular mechanism of apoptosis and gene expressions in human lymphoma U937 cells treated with anisomycin. Chem Biol Interact 2008; 172:125-40; PMID:18241849; http://dx.doi.org/10.1016/j.cbi.2007.12.003.
17. Croons V, Martinet W, Herman AG, Timmermans JP, De Meyer GR. The protein synthesis inhibitor anisomycin induces macrophage apoptosis in rabbit atherosclerotic plaques through p38 mitogen-activated protein kinase. J Pharmacol Exp Ther 2009; 329:856-64; PMID:19286921; http://dx.doi.org/10.1124/ jpet.108.149948.
18. Tang Z, Xing F, Chen D, Yu Y, Yu C, Di J, et al. In vivo toxicological evaluation of Anisomycin. Toxicol Lett 2011; PMID:22004851.
19. Nesbit M, Nesbit HK, Bennett J, Andl T, Hsu MY, Dejesus E, et al. Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes. Oncogene 1999; 18:6469-76; PMID:10597249; http://dx.doi.org/10. 1038/sj.onc.1203066.
20. Fodstad O, Kjønniksen I, Aamdal S, Nesland JM, Boyd MR, Pihl A. Extrapulmonary, tissue-specific metastasis formation in nude mice injected with FEMX-I human melanoma cells. Cancer Res 1988; 48:4382-8; PMID:3390834.
21. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58:621-81; PMID:16968952; http://dx.doi.org/10.1124/pr.58.3.10.
22. Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, et al. The proteasome inhibitor PS-341 (bortezomib) upregulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res 2007; 67:4981-8; PMID:17510429; http://dx.doi.org/10.1158/0008-5472.CAN-06-4274.
23. Nikolaou VA, Stratigos AJ, Flaherty KT, Tsao H. Melanoma: new insights and new therapies. J Invest Dermatol 2012; 132:854-63; PMID:22217739; http://dx.doi.org/10.1038/jid.2011.421.
24. Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Zhang XD, Thompson JF, et al. Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand. Hum Pathol 2006; 37:1286-94; PMID:16949935; http://dx.doi.org/10.1016/j.humpath. 2006.04.026.
25. Hersey P, Zhang XD. How melanoma cells evade trail-induced apoptosis. Nat Rev Cancer 2001; 1:142-50; PMID:11905805; http://dx.doi.org/10.1038/35101078.
26. Ivanov VN, Zhou H, Hei TK. Sequential treatment by ionizing radiation and sodium arsenite dramatically accelerates TRAIL-mediated apoptosis of human melanoma cells. Cancer Res 2007; 67:5397-407; PMID:17545621; http://dx.doi.org/10.1158/0008-5472.CAN-07-0551.
27. Phipps LE, Hino S, Muschel RJ. Targeting cell spreading: a method of sensitizing metastatic tumor cells to TRAIL-induced apoptosis. Mol Cancer Res 2011; 9:249-58; PMID:21296861; http://dx.doi.org/10.1158/1541-7786.MCR-11-0021.
28. Kluger HM, McCarthy MM, Alvero AB, Sznol M, Ariyan S, Camp RL, et al. The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. J Transl Med 2007; 5:6; PMID:17257402; http://dx.doi.org/10.1186/ 1479-5876-5-6.
29. Chen N, Gong J, Chen X, Meng W, Huang Y, Zhao F, et al. Caspases and inhibitor of apoptosis proteins in cutaneous and mucosal melanoma: expression profile and clinicopathologic significance. Hum Pathol 2009; 40:950-6; PMID:19269012; http://dx.doi.org/10.1016/j.humpath.2008.12.001.
30. Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, et al. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res 2009; 69:2425-34; PMID:19258513; http://dx.doi.org/10.1158/0008-5472.CAN-08-2436.
31. Takeuchi H, Morton DL, Elashoff D, Hoon DS. Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine. Int J Cancer 2005; 117:1032-8; PMID:15986442; http://dx.doi.org/10.1002/ijc.21267.
32. Thayaparasingham B, Kunz A, Peters N, Kulms D. Sensitization of melanoma cells to TRAIL by UVBinduced and NF-kappaB-mediated downregulation of xIAP. Oncogene 2009; 28:345-62; PMID:18978816; http://dx.doi.org/10.1038/onc.2008.397.
33. Engesæter BO, Sathermugathevan M, Hellenes T, Engebråten O, Holm R, Flørenes VA, et al. Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells. Cancer Biol Ther 2011; 12:47-58; PMID:21508672; http://dx.doi.org/10.4161/cbt.12.1.15714.
34. Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, Borden EC. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 2004; 11:915-23; PMID:15118763; http://dx.doi.org/10.1038/sj.cdd.4401416.
35. Nachmias B, Ashhab Y, Bucholtz V, Drize O, Kadouri L, Lotem M, et al. Caspase-mediated cleavage converts Livin from an antiapoptotic to a proapoptotic factor: implications for drug-resistant melanoma. Cancer Res 2003; 63:6340-9; PMID:14559822.
36. Sung B, Ravindran J, Prasad S, Pandey MK, Aggarwal BB. Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL. J Biol Chem 2010; 285:35418-27; PMID:20837473; http://dx.doi.org/10.1074/jbc.M110.172767.
37. Prasad S, Ravindran J, Sung B, Pandey MK, Aggarwal BB. Garcinol potentiates TRAIL-induced apoptosis through modulation of death receptors and antiapoptotic proteins. Mol Cancer Ther 2010; 9:856-68; PMID:20371723; http://dx.doi.org/10.1158/1535-7163.MCT-09-1113.
38. Mawji IA, Simpson CD, Gronda M, Williams MA, Hurren R, Henderson CJ, et al. A chemical screen identifies anisomycin as an anoikis sensitizer that functions by decreasing FLIP protein synthesis. Cancer Res 2007; 67:8307-15; PMID:17804746; http://dx.doi.org/10.1158/0008-5472.CAN-07-1687.
39. Mikhailov A, Patel D, McCance DJ, Rieder CL. The G2 p38-mediated stress-activated checkpoint pathway becomes attenuated in transformed cells. Curr Biol 2007; 17:2162-8; PMID:18060783; http://dx.doi.org/10.1016/j.cub.2007. 11.028.
40. Xu J, Zhou JY, Wei WZ, Wu GS. Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells. PLoS One 2010; 5:e10226; PMID:20419107; http://dx.doi.org/10.1371/journal. pone.0010226.
41. Zhang XD, Borrow JM, Zhang XY, Nguyen T, Hersey P. Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene 2003; 22:2869-81; PMID:12771938; http://dx.doi.org/10.1038/sj.onc.1206427.